RPRX vs. XBI
RPRX (Royalty Pharma plc) is a stock, while XBI (SPDR S&P Biotech ETF) is Health & Biotech Equities fund tracking the S&P Biotechnology Select Industry Index. Over the past 5 years, RPRX returned 9.13%/yr vs 4.42%/yr for XBI. At a 0.37 correlation, their price movements are largely independent.
Performance
RPRX vs. XBI - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, RPRX achieves a 47.51% return, which is significantly higher than XBI's 27.53% return.
RPRX
- 1D
- 0.04%
- 1M
- 2.88%
- 6M
- 41.57%
- YTD
- 47.51%
- 1Y
- 60.89%
- 3Y*
- 25.75%
- 5Y*
- 9.13%
- 10Y*
- —
XBI
- 1D
- -2.32%
- 1M
- 16.22%
- 6M
- 25.47%
- YTD
- 27.53%
- 1Y
- 79.33%
- 3Y*
- 22.80%
- 5Y*
- 4.42%
- 10Y*
- 10.68%
RPRX vs. XBI - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
RPRX Royalty Pharma plc | 47.51% | 55.29% | -6.36% | -27.08% | 0.99% | -19.09% | 14.62% |
XBI SPDR S&P Biotech ETF | 27.53% | 35.89% | 1.01% | 7.60% | -25.87% | -20.45% | 36.89% |
Correlation
The correlation between RPRX and XBI is 0.32, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.32 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.33 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.36 |
Correlation (All Time) Calculated using the full available price history since Jun 16, 2020 | 0.37 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RPRX vs. XBI — Risk / Return Rank
RPRX
XBI
RPRX vs. XBI - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Royalty Pharma plc (RPRX) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RPRX | XBI | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.27 | ||
| Sortino ratioReturn per unit of downside risk | -0.32 | ||
| Omega ratioGain probability vs. loss probability | 1.45 | 1.46 | -0.01 |
| Calmar ratioReturn relative to maximum drawdown | 8.29 | 8.20 | +0.09 |
| Martin ratioReturn relative to average drawdown | 20.34 | 24.14 | -3.79 |
Loading charts...
Drawdowns
RPRX vs. XBI - Drawdown Comparison
The maximum RPRX drawdown since its inception was -49.68%, smaller than the maximum XBI drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for RPRX and XBI.
Loading charts...
Drawdown Indicators
| RPRX | XBI | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -49.68% | -63.89% | +14.21% |
Max Drawdown (1Y)Largest decline over 1 year | -7.38% | -9.72% | +2.34% |
Max Drawdown (3Y)Largest decline over 3 years | -20.67% | -32.99% | +12.32% |
Max Drawdown (5Y)Largest decline over 5 years | -41.98% | -54.00% | +12.02% |
Max Drawdown (10Y)Largest decline over 10 years | — | -63.89% | — |
Current DrawdownCurrent decline from peak | -3.29% | -10.13% | +6.84% |
Average DrawdownAverage peak-to-trough decline | -26.00% | -20.90% | -5.10% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.00% | 3.30% | -0.30% |
Volatility
RPRX vs. XBI - Volatility Comparison
Royalty Pharma plc (RPRX) and SPDR S&P Biotech ETF (XBI) have volatilities of 8.03% and 8.14%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| RPRX | XBI | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.03% | 8.14% | -0.11% |
Volatility (6M)Calculated over the trailing 6-month period | 15.07% | 21.33% | -6.26% |
Volatility (1Y)Calculated over the trailing 1-year period | 22.52% | 26.72% | -4.20% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 23.90% | 32.33% | -8.43% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 26.87% | 31.94% | -5.07% |
Dividends
RPRX vs. XBI - Dividend Comparison
RPRX's dividend yield for the trailing twelve months is around 1.61%, more than XBI's 0.37% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
RPRX Royalty Pharma plc | 1.61% | 2.28% | 3.29% | 2.85% | 1.92% | 1.71% | 0.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
XBI SPDR S&P Biotech ETF | 0.37% | 0.37% | 0.15% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% |
Frequently Asked Questions
RPRX and XBI have a correlation of 0.32, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
XBI has higher volatility (8.14%) compared to RPRX (8.03%). In terms of maximum drawdown, RPRX dropped -49.68% vs XBI's -63.89%.
XBI currently has the higher Sharpe Ratio (2.99 vs 2.72), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for RPRX and XBI
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer